{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-204161","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.685360+00:00","generated_at":"2026-05-15T00:09:15.337101+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Perspective Therapeutics updates VMT-α-NET Ph1/2a data and preliminary cash position","bullets":["Preliminary cash & short-term investments as of Mar 31, 2026 disclosed; unaudited, subject to final adjustments.","VMT-α-NET Phase 1/2a data show durable disease control across all doses; responses deepen over time.","Company says profile supports potential registration study at current dose level.","Manufacturing update: daily production at regional sites for ready-to-administer 212Pb products.","Expanding pipeline includes CCK2R81 targeting and other solid tumor programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-204161","json":"https://secwatch.observer/filing/0001193125-26-204161.json","markdown":"https://secwatch.observer/filing/0001193125-26-204161.md","text":"https://secwatch.observer/filing/0001193125-26-204161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526204161/0001193125-26-204161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526204161/catx-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:09:15.337101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}